• Motixafortide regimen shows ‘impressive' activity in transplant setting for myeloma

    2 days ago - By Healio

    The addition of motixafortide to standard treatment improved hematopoietic stem cell target mobilization for autologous bone marrow transplantation among patients with multiple myeloma, according to the agent's manufacturer.
    The randomized phase 3 GENESIS trial included 122 patients with multiple myeloma.
    Patients received granulocyte colony-stimulating factor plus either motixafortide or placebo.
    Researchers' primary objective was to demonstrate that one dose of motixafortide plus G-CSF would prove superior to G-CSF alone in its ability to mobilize at least
    Read more ...

     

  • Bone Loss can be Managed Efficiently After Hematopoietic Stem Cell Transplantation

    Bone Loss can be Managed Efficiently After Hematopoietic Stem Cell Transplantation

    2 days ago - By Medindia Health

    International Osteoporosis Foundation provides guidance for the management of impaired bone health that result as the long term consequence of HSCT
    Read more ...